Kornimate/medical-research-clean huggingface dataset:
lung cancer screening eligibility assessment

Conditions: Lung Cancer

Summary: the primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (lcs). this will help inform the best way to increase response rates to the tool in future intervention studies designed to increase lcs, and expand upon survey methodology in general.

despite growing evidence that lung cancer screening (lcs) reduces lung cancer-specific mortality, lcs across the united states is remarkably low. this is due in part to challenges with identifying adults who meet eligibility criteria for lifetime smoking intensity (i.e., 20 pack-years or greater), which is often missing from the electronic medical record. we have developed a simplified eligibility tool that has shown accuracy in estimating pack-years. but given the potential for low response rates, there is a great need to identify effective strategies to increasing response rates equitably prior to using it in practice or in future studies. the primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (lcs). this will help to identify the best way to increase response rates to the tool in future intervention studies designed to increase lcs, and expand upon survey methodology in general.

Eligibility criteria:
inclusion criteria: 1. meet age eligibility (50-80 years old) for lcs based on 2021 uspstf guidelines; and 2. have completed at least one primary care visit at penn medicine in 2020-2025 exclusion criteria: 1. have a documented history of lung cancer; 2. have a documented history of completing lcs at penn medicine; 3. are listed as not wanting to be contacted or solicited for research; or 4. do not otherwise meet inclusion criteria.

Keywords: lung cancer screening
coping and adjusting to living with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this project is to test a brief, telephone-based psychological intervention, cbt-ut, to improve the ability to tolerate uncertainty-and thereby to reduce distress-in people with a recent diagnosis of multiple sclerosis (ms). there are three treatment arms for this study. participants will receive either (1) cbt for uncertainty tolerance, (2) traditional cbt, or (3) treatment as usual.

despite substantial improvements in diagnosis and treatment, multiple sclerosis (ms) remains an unpredictable disease. although some physicians can make some predictions about expected progression, the variable course of exacerbations makes it almost impossible to predict how ms will develop or affect function over time. as a result, people with ms must learn to live in a state of chronic uncertainty and the ability to tolerate and cope with this kind of uncertainty is central to quality of life with ms. individuals who require certainty about the future and are not able to tolerate ambiguity are said to be high in a personality trait known as intolerance of uncertainty (iu). there is a significant gap in ms clinical intervention that necessitates attention. an intervention that specifically targets iu, is developed for people recently diagnosed with ms, and can be provided remotely via telehealth can make a significant impact for this population. study aims include: (1) to determine the efficacy of cbt-ut relative to traditional cognitive behavioral therapy (tcbt) or treatment as usual (tau) in people diagnosed with ms in the past 3 years; and (2) to increase our understanding of the mechanisms underlying the intervention effects.

Eligibility criteria:
inclusion criteria: * adults over 18 years of age * ms diagnosis using revised mcdonald criteria * able to read, speak, and understand english * at least mild psychological distress evidenced by (1) a score of 20 or higher on the kessler psychological distress scale or (2) a score greater than or equal to 5 on the perceived stress scale. exclusion criteria: * severe cognitive impairment defined as one or more error on the six-item screener * psychiatric condition or symptoms that would interfere with participation, specifically (1) current, active suicidal ideation with current intent to harm oneself, (2) current psychosis, or (3) current mania.
atrial fibrillation detecting software gung atrial fibrillation detecting software

Conditions: Atrial Fibrillation

Summary: chang gung atrial fibrillation detection software is an artificial intelligence electrocardiogram signal analysis software that detects whether a patient has atrial fibrillation by static 12-lead ecg signals. this study is a non-inferiority test based on the control group. the main purpose is to verify whether chang gung atrial fibrillation detection software can correctly identify atrial fibrillation in patients with atrial fibrillation, and can be used to provide a reference for doctors to detect atrial fibrillation.

this study is a retrospective study, and the data is from the six hospitals of chang gung medical research database (cgrd). we collected de-identified static 12-lead electrocardiogram (ecg) data from the database during the period of january 1, 2006, to december 31, 2019. we created a training set and a testing set of ecg data from the cgrd. then, we stratified and sampled ecg signals from the testing set according to the actual proportion to obtain the experimental sample. the computer first preliminarily screened and selected ecg data that met the inclusion and exclusion criteria, and then numbered them sequentially. a cardiologist confirmed that the sampled ecg data did not include exclusion criteria. the ecg data were converted into images and interpreted for the presence or absence of atrial fibrillation by three cardiologists. their results were used as the gold standard (reference) for this study. after determining the experimental standards, the ecg signals were inputted into the chang gung atrial fibrillation detection software for analysis and interpretation of each ecg data. after the software interpretation was completed, the results were compared with the interpretations of the physicians, and the primary and secondary evaluation indicators were analyzed accordingly.

Eligibility criteria:
inclusion criteria: * equal or greater than twenty years old * static 12-lead electrocardiogram of general electric muse xml format file. * the data comes from the static 12-lead electrocardiogram device of general electric (model mac5500). * the electrocardiogram signal is 500 hz. * the alternating current (ac) filter of the electrocardiogram signal is 60 hz. exclusion criteria: * cases used in the model development process. * lacks any electrode. * contain any electrode lacks a segment. * misplaced leads

Keywords: artificial intelligence
drug delivery and toxicities of adjuvant chemotherapy in resected ncslc

Conditions: Adjuvant; Chemotherapy; Lung; Cancers

Summary: there are limited numbers of retrospective studies showing the effectiveness of adjuvant chemotherapy over observation in resected lung cancers.

we propose to retrospectively examine the washington university school of medicine experience on all patients receiving adjuvant chemotherapy between 2003 and 2005. we will retrospectively analyze the survival and outcomes in the lung cancer patients receiving adjuvant chemotherapy following surgical resection.

Eligibility criteria:
inclusion criteria: * patients that received adjuvant chemotherapy * 18-88 years exclusion criteria: * any patients that have not received adjuvant chemotherapy * patients under 18 or over 88

Keywords: adjuvant chemotherapy observation resected cancers
optimising renal tumour management through artificial intelligence modules

Conditions: Renal Neoplasms; Pathology; Renal Cell Cancer

Summary: the goal of this observational study is to improve the management of people with renal tumour by multimodal artificial intelligence(ai). it will also measure the accuracy of the predictions from ai models. the main questions it aims to answer are: 1. whether the ai module can accurately provide tumor-related information such as benign or malignant, subtypes, grading, stage, etc. by learning from preoperative ct images. 2. whether the ai module can help clinicians find out the most suitable surgical programme for people with renal tumor. 3. whether the ai module can integrate ct images and pathology slides, offering supplementary prognostic information to improve postoperative survival. participants who complete a ct(usually contrast-enhanced ct, cect) examination and undergo radical or partial nephrectomy will carry out active surveillance and record postoperative survival data for 5 years.

in this study, ai model will explore and clarify features in renal tumor ct images and pathological images that are difficult to detect manually, and then correlate them with clinical outcomes, thereby improving the diagnosis and treatment process for renal tumors. firstly, the model can accurately distinguish renal tumor subtypes and predict stage, grade, and complexity so as to svoid misdiagnosis and assist clinicians in formulating treatment plans. secondly, by learning from surgical videos, the model can provide additional information during surgerys, such as important anatomical landmarks, location of tumors. finally, combining radiomics and pathomics, the model can differentiate between high-risk and low-risk patients after surgery, thus providing personalized prognostic guidance.

Eligibility criteria:
inclusion criteria: * patients with renal tumor which can be treated by surgery; * complete cect within 30 days before surgery; * patients who fully understand this study and sign the informed consent; exclusion criteria: * patients with any item missing from the baseline clinical and pathological information; * patients who has already metastasized by the time the tumor is discovered; * previous treatment in any form, including surgery, targeted therapy and immunotherapy;

Keywords: articicial intelligence renal tumors prediction model surgery radiomics pathomics
continuous tibial nerve block versus single shot tibial nerve block

Conditions: Hallux Valgus

Summary: foot surgery often causes severe and prolonged pain postoperatively. prior methods of postoperative pain control included oral narcotics, single injection regional techniques and more recently continuous nerve catheters. recent studies have demonstrated a benefit with continuous popliteal catheters when compared to single injection techniques in regards to postoperative pain control and patient satisfaction for foot surgeries. nerve blocks in the popliteal fossa involve both the common peroneal nerve and the tibial nerve. the innervation to the plantar surface of the forefoot involves the tibial nerve and does not involve the peroneal nerve. the purpose of this study is to compare the continuous posterior tibial nerve catheter with a single injection posterior tibial nerve block when used as part of a surgical ankle block for forefoot surgery.


Eligibility criteria:
inclusion criteria: * adult patients (18 to 65 years old) undergoing elective scheduled forefoot surgery (hallux valgus repair and metatarsal osteotomy). exclusion criteria: * patient refusal to be included * presence of language barrier that prohibits proper communication with patient * under age of 18, * pregnancy * history of allergy to local anesthetics or opioids * presence of a progressive neurological deficit * chronic opioid or drug abuse * diabetes * active infection in leg * unstable cardiovascular, renal or hepatic disease, * unwillingness to comply with follow up.

Keywords: forefoot surgery
energy for lymphocytes

Conditions: Non-small Cell Lung Cancer; Progression, Disease

Summary: certim is a cohort created in july 2015 to set up a multidisciplinary follow-up of cancer patients treated with immune checkpoint inhibitors. from the certim cohort, we conducted a longitudinal, prospective, observational study (ely) in two tertiary university centers (cochin hospital and european georges pompidou hospital), which included patients between august 2016 and october 2019 and ended follow-up in april 2020. patients were treated with nivolumab, at a dose of 3 mg/kg every 2 weeks, or pembrolizumab, at a dose of 2mg/kg every 3 weeks. the investigators report findings from an evaluation of rest energy expenditure (ree) assessed using indirect calorimetry in the outpatient setting before treatment with checkpoints inhibitors.


Eligibility criteria:
inclusion criteria: * 18 years or older * stage iv histologically proven non small cell lung cancer (nsclc) * monotherapy with nivolumab or pembrolizumab. * patients were required to have measurable disease per the response evaluation criteria in solid tumors (recist), version 1.1. exclusion criteria: * active malignancy other than nsclc, * alk or egfr mutated nsclc * anticancer therapy or surgery within the past 2 weeks or inability to breathe under the calorimetry.

Keywords: cachexia immunotherapy carcinoma non-small cell lung cancer basal metabolism energy expenditure inflammation 6-month progression free survival
screening expiratory flow limitation by flow-time curve

Conditions: ARDS, Human

Summary: expiratory flow limitation (efl) is defined as a dynamic condition that expiratory flow cannot be further increased with higher expiratory driving pressure. under mechanical ventilation, it can cause intrinsic positive end-expiratory pressure (peep) and dynamic hyperinflation, and be associated with worse clinical outcome. the detection of efl however needs special maneuvers and offline analysis of flow-volume curves, which are infeasible in routine practice and cannot be used during real-time monitoring. the investigators propose a new and simple approach using flow derived parameters to detect efl in real time without needing any intervention.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years, intubated or tracheostomized 2. receiving invasive mechanical ventilation in assist/control mode with peep ≥ 5 cmh2o 3. receiving continuous intravenous sedation 4. displaying a monotonous regular breathing pattern with no obvious asynchrony exclusion criteria: 1. severe hypoxemia in baseline clinical ventilator settings (spo2 \< 90%) 2. hemodynamic instability (mabp \ 180 mmhg, heart rate \ 150/min)
pozelimab and cemdisiran combination treatment in adult participants with paroxysmal nocturnal hemoglobinuria who have received pozelimab monotherapy

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Summary: the primary objective of the study is to evaluate the safety and tolerability of 2 dosing regimens of pozelimab and cemdisiran combination therapy during the open-label treatment period (oltp) the secondary objectives of the study are: * to evaluate the effect of the combination treatment on the following parameters of intravascular hemolysis: lactate dehydrogenase (ldh) control, breakthrough hemolysis, and inhibition of total complement hemolysis activity (ch50) * to evaluate the effect of the combination treatment on hemoglobin levels * to evaluate the effect of the combination treatment on red blood cell (rbc) transfusion requirements * to evaluate the effect of the combination treatment on clinical outcome assessments (coas) measuring fatigue and health related quality of life * to assess the concentrations of total pozelimab in serum and total complement component (c) 5 and cemdisiran in plasma * to assess immunogenicity to pozelimab and cemdisiran * to evaluate the long-term safety and efficacy of pozelimab and cemdisiran in an optional open-label extension period (olep) * to assess safety after treatment intensification with pozelimab and cemdisiran


Eligibility criteria:
key inclusion criteria: 1. participants with pnh who are receiving treatment with pozelimab monotherapy in the r3918- pnh-1868 study (nct04162470) key exclusion criteria: 1. documented, positive polymerase chain reaction (pcr) or equivalent test based on regional recommendations for covid-19 or suspected sars-cov-2 infection as defined in the protocol 2. participants with documented history of liver cirrhosis or participants with liver disease with evidence of currently impaired liver function; or participants with alanine aminotransferase (alt) or aspartate aminotransferase (ast) as described in the protocol 3. significant protocol deviation(s) in the parent study based on the investigator's judgment as described in the protocol 4. any new condition or worsening of an existing condition which, in the opinion of the investigator, would make the participant unsuitable for enrollment or would jeopardize the safety of the participant 5. known hypersensitivity to cemdisiran or any component of cemdisiran formulation note: other protocol-defined inclusion/ exclusion criteria apply

Keywords: pnh
health equity and rural education (here!) clinical trial

Conditions: Behavioral Symptoms; Community Health Workers; Social Determinants of Health; Educational Problems

Summary: the goal of this community-engaged research is two-fold. the first goal is to gather stakeholder feedback to inform a school-based community health worker intervention with youth with poor school attendance and an enhanced usual care condition. the second goal is to evaluate the feasibility of implementing the school-based community health worker intervention and enhanced usual care approach within rural schools. the main question it aims to answer is whether it is feasibile to recruit children with poor school attendance and their families to the intervention, to complete the trauma-informed intervention, and to complete the associated study measures of meeting social determinants of health/mental health needs, school-based health center utilization, and behavioral helath symptoms. at least 38 rural students in grades 6-12 with poor school attendance and their parents/guardians will meet with the school-based community health worker for support around social determinants of health needs that may be barriers to attendance. researchers will also assess the feasibility of recruiting at least 10 rural students and their parents/guardians to complete the study measures in an enhanced usual care condition in which the school-based health center without a school-based community health worker is reminded of the availability of an online social services directory.

the here pilot study will consist of two phases to strengthen and finalize the here school-based community health worker (sb-chw) intervention. the 6-month phase i will provide broad stakeholder feedback on the proposed model and rationale, the sb-chw intervention, the associated domains and measures, and the evaluation. the following 18-month phase ii will align with the school year and provide a feasibility test of the training, intervention, data collection, and analyses.

Eligibility criteria:
phase i stakeholder interviews (nonintervention): inclusion criteria: * a member of the program's community advisory board, including community health workers; * caregiver of a child ages 12-18 from the southeast kansas region; or * student at least 12 years in age. phase ii feasibility pilot- sb-chw intervention and enhanced usual care conditions inclusion criteria: * children in grades 6-12 (ages 12-18) and their parents/guardians from the southeast kansas region * student with or at risk for chronic poor attendance (missing 10% or more of the days that school has been in session at any point in the school year) exclusion criteria: * parents/guardians or youth with profound intellectual/cognitive disability will be excluded.
the body's response to changes in dietary protein and meal-frequency in men

Conditions: Low Protein Dietary Intake; High Protein Dietary Intake

Summary: the purpose of this study is to identify how the body responds to increased dietary protein (that includes pork and eggs) and meal-frequency in adult men. during this study, the changes in blood glucose, hormones, appetite, and energy expenditure will be examined.


Eligibility criteria:
inclusion criteria: * 21 and older, bmi between 25.0-34.6, weight stable for at least 6 mths, body \>25%, non smoking, clinically normal blood profiles, non-diabetic. exclusion criteria: * intermittently been involved in a diet and/or exercise program within the last 3 months, have no allergies to eggs.

Keywords: overweight, protein intake, satiety, eating, meal patterns
immunotherapy of melanoma patients

Conditions: Melanoma

Summary: the purpose of this study is to test whether vaccination with antigenic peptides induces an immune response in the vaccine site sentinel lymph node of patients with microscopically detectable lymph node melanoma metastases.

the study is designed for patients with skin melanoma and lymph node micrometastasis previously diagnosed by a sentinel node procedure. as a result of their diagnosis, the patients are scheduled for lymph node dissection. before this is done, patients are vaccinated with antigenic peptides. the peptides are mixed with the adjuvant sb as-2 or montanide and injected in a lower limb not affected by the disease. the skin site of vaccine injection is marked with a permanent pen where, two weeks later, patent blue and 99technetium is injected. these markers allow one to locate the vaccine site sentinel node (vssn) which will be removed during the lymph node dissection at the diseased limb. the aim of the study is to test whether the vaccine has induced an immune response in the lymph node that drains the vaccine site.

Eligibility criteria:
inclusion criteria: * patients with microscopically detectable lymph node metastases * positive detection of the melan-a gene +/- mage-10 in positive sentinel node or primary tumor tissue by polymerase chain reaction (pcr) analysis of mrna and/or by immunohistochemistry using monoclonal antibodies * human leukocyte antigen-a2 (hla-a2) positive exclusion criteria: * previous splenectomy or radiotherapy to the spleen * treatment with systemic antihistamines, corticosteroids, or non-steroidal anti-inflammatory drugs (except occasional or low dose non-steroidal anti-inflammatory drugs such as 100 mg aspirin/day) within 4 weeks of entry into the study * heart disease (new york heart association \[nyha\] class iii or iv) * serious illness, e.g. active infections requiring antibiotics, bleeding disorders or other diseases considered by the investigator to have potential for interfering with obtaining accurate results from this study

Keywords: immunotherapy vaccination melanoma melan-a/mart-1 peptide flu peptide mage-a10 peptide sb as-2 adjuvant montanide adjuvant
effect of low level laser therapy after wisdom tooth removal

Conditions: Tooth, Impacted; Wound Heal; Quality of Life

Summary: the aim is to test the effect of low level laser therapy on the relief of symptoms after wisdom tooth removal.

each patient will get all four wisdom teeth removed, left and right side separately. after the operation, low level laser therapy is applied intra- and extraorally. two different lasers are used, one for each side. the two lasers look identical. only one of the lasers has therapeutic light, the other one shows just non-therapeutic red light. the effect of the low level laser is measured by several parameters and they are compared with the other side. these parameters are pain, swelling and mouth opening. the selection of the lasers to the sides is double-blind and randomized.

Eligibility criteria:
inclusion criteria: * indication for prophylactical wisdom tooth removal * 4 wisdom teeth exclusion criteria: * pregnancy * taking blood thinners * known infectious diseases * untreated diabetes mellitus * taking immunosuppressants * previous infections in the area of the wisdom teeth * smoking

Keywords: wisdom tooth low level laser